CN103880965B - 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 - Google Patents

被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 Download PDF

Info

Publication number
CN103880965B
CN103880965B CN201410160383.9A CN201410160383A CN103880965B CN 103880965 B CN103880965 B CN 103880965B CN 201410160383 A CN201410160383 A CN 201410160383A CN 103880965 B CN103880965 B CN 103880965B
Authority
CN
China
Prior art keywords
ifn
igg3
her2
cells
neu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410160383.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103880965A (zh
Inventor
谢里.L.默里森
黄子轩
旋采云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN103880965A publication Critical patent/CN103880965A/zh
Application granted granted Critical
Publication of CN103880965B publication Critical patent/CN103880965B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201410160383.9A 2007-09-21 2008-09-19 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 Active CN103880965B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99471707P 2007-09-21 2007-09-21
US60/994,717 2007-09-21
CN200880117225A CN101868246A (zh) 2007-09-21 2008-09-19 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880117225A Division CN101868246A (zh) 2007-09-21 2008-09-19 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性

Publications (2)

Publication Number Publication Date
CN103880965A CN103880965A (zh) 2014-06-25
CN103880965B true CN103880965B (zh) 2018-02-16

Family

ID=40468388

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201410160383.9A Active CN103880965B (zh) 2007-09-21 2008-09-19 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
CN201810058393.XA Active CN108129573B (zh) 2007-09-21 2008-09-19 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
CN200880117225A Pending CN101868246A (zh) 2007-09-21 2008-09-19 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810058393.XA Active CN108129573B (zh) 2007-09-21 2008-09-19 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
CN200880117225A Pending CN101868246A (zh) 2007-09-21 2008-09-19 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性

Country Status (12)

Country Link
US (5) US9139634B2 (enExample)
EP (3) EP2853267B1 (enExample)
JP (3) JP5591701B2 (enExample)
KR (2) KR101661770B1 (enExample)
CN (3) CN103880965B (enExample)
AU (1) AU2008302111B2 (enExample)
BR (1) BRPI0817108B8 (enExample)
CA (1) CA2699944C (enExample)
ES (1) ES2536772T3 (enExample)
IL (2) IL204644A (enExample)
MX (2) MX2010003099A (enExample)
WO (1) WO2009039409A1 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185589B1 (en) 2007-06-01 2016-01-06 University of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
EP3492488A1 (en) 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
KR101661770B1 (ko) 2007-09-21 2016-10-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함
WO2010081173A2 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
RU2012127383A (ru) * 2009-12-02 2014-01-10 Акселерон Фарма Инк. Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке
ES2611479T3 (es) * 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Anticuerpos contra endoplasmina y su uso
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
WO2012170072A1 (en) 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
EP2718328A4 (en) * 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
WO2013096346A1 (en) * 2011-12-22 2013-06-27 Development Center For Biotechnology Bispecific t-cell activator antibody
US9492562B2 (en) 2012-01-20 2016-11-15 Vib Vzw Targeted human-interferon fusion proteins
PL2822575T3 (pl) * 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
EP4219536A3 (en) * 2012-04-30 2023-08-23 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
US20150166654A1 (en) 2012-05-30 2015-06-18 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2014028502A1 (en) * 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
WO2014031646A2 (en) * 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
WO2014089354A1 (en) * 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
PT2970512T (pt) 2013-03-12 2019-01-17 Biocon Ltd Proteínas de fusão imunomoduladoras e métodos para produção das mesmas
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
US20160237156A1 (en) 2013-07-11 2016-08-18 The California Institute For Biomedical Research Immunoglobulin fusion proteins and compositions thereof
CN105705641B (zh) 2013-07-18 2021-07-13 弗拉芒区生物技术研究所 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子
JP6475712B2 (ja) 2013-07-19 2019-02-27 ヴィブ ブイゼットダブリュー サイトカインアンタゴニストの標的化
BR112016001114B1 (pt) 2013-07-19 2023-02-14 Vib Vzw Composição compreendendo uma proteína de fusão e uso da referida composição
MX370348B (es) 2013-07-19 2019-12-10 Vib Vzw Miembros de la familia il-1 modificados dirigidos.
EP4137519A1 (en) * 2013-08-09 2023-02-22 The Trustees Of The University Of Pennsylvania Fusion protein comprising ifn-gamma and anti-erbb antibody for the treatment of cancers
US11446516B2 (en) 2013-08-09 2022-09-20 The Trustees Of The University Of Pennsylvania Methods of increasing response to cancer radiation therapy
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
CA2927543C (en) 2013-10-15 2021-07-20 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
TW202446953A (zh) 2013-12-04 2024-12-01 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
WO2016081601A1 (en) * 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of epha2
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
US20170002057A1 (en) * 2015-02-26 2017-01-05 Nal Pharmaceutical Group Limited Compositions containing fusion protein of albumin and analogs thereof, methods for making and using the same
US20210009720A1 (en) * 2015-03-03 2021-01-14 Genopharm Inc. Human interferon-beta variant conjugated immunocytokine and method for preparing same
KR101838919B1 (ko) 2015-03-03 2018-03-15 에이비온 주식회사 인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
WO2016201251A1 (en) * 2015-06-12 2016-12-15 Immungene, Inc. Focused interferon immunotherapy for treatment of cancer
MX394116B (es) 2015-07-24 2025-03-19 Gliknik Inc Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada.
JP6452577B2 (ja) * 2015-08-27 2019-01-16 株式会社沖データ 画像形成装置
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
EP3402509A4 (en) * 2016-01-14 2019-07-10 Seattle Children's Hospital (DBA Seattle Children's Research Institute) TUMOR SPECIFIC IFNA SECRETION BY CAR T CELLS FOR RESTORING SOLID TUMOR MICRO ENVIRONMENT
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
WO2017180764A1 (en) * 2016-04-12 2017-10-19 Immungene, Inc. Focused interferon immunotherapy
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
EP3454887B1 (en) 2016-05-13 2021-01-20 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
EP3487522A4 (en) 2016-07-19 2020-04-01 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
ES3030503T3 (en) 2016-10-19 2025-06-30 Scripps Research Inst Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
AU2017371182B2 (en) 2016-12-09 2024-03-28 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
RU2766582C2 (ru) * 2016-12-23 2022-03-15 Ремд Биотерапьютикс, Инк. Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
US11246911B2 (en) 2017-02-07 2022-02-15 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
CN117924493A (zh) 2017-08-09 2024-04-26 奥里尼斯生物科学有限公司 Clec9a结合剂及其用途
JP7347899B2 (ja) 2017-08-09 2023-09-20 オリオンズ バイオサイエンス インコーポレイテッド Ｃｄ８結合物質
CN119285770A (zh) 2017-08-09 2025-01-10 奥里尼斯生物科学有限公司 Pd-1和pd-l1结合剂
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
WO2019182996A1 (en) * 2018-03-19 2019-09-26 The Regents Of The University Of California Antibody-interferon fusion proteins for enhancing adoptive t cell therapies for the treatment of cancer
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
EP3835321A4 (en) 2018-08-10 2022-11-02 Chugai Seiyaku Kabushiki Kaisha ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
JP2022524018A (ja) * 2019-03-06 2022-04-27 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
KR20210021861A (ko) * 2019-08-19 2021-03-02 (주)제노팜 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법
WO2021097376A1 (en) * 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
AU2020398327A1 (en) 2019-12-03 2022-07-14 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
US20230310581A1 (en) * 2020-04-27 2023-10-05 Ohio State Innovation Foundation A live attenuated measles virus vectored vaccine for sars-cov-2
IL300062A (en) 2020-07-20 2023-03-01 Deka Biosciences Inc Dual fused cytokine proteins containing IL-10
KR20240135599A (ko) * 2021-08-12 2024-09-11 상하이 제이엠티-바이오 테크노로지 컴퍼니 리미티드 GPC3 표적 항체-인터페론α 융합 단백질 및 이의 용도
KR20240015035A (ko) * 2022-07-25 2024-02-02 충남대학교산학협력단 클로로톡신의 분비를 위한 재조합 발현 벡터 및 이로형질전환된 약독화 살모넬라 균주
EP4573110A1 (en) 2022-08-18 2025-06-25 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024238415A1 (en) 2023-05-12 2024-11-21 Regeneron Pharmaceuticals, Inc. Interferon receptor antagonists and uses thereof
WO2025106883A1 (en) * 2023-11-15 2025-05-22 President And Fellows Of Harvard College Engineered fc-prolactin fusions to increase lactation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097844A1 (en) * 2000-06-22 2001-12-27 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
CN1751122A (zh) * 2003-02-18 2006-03-22 默克专利有限公司 具有改进特性的干扰素α突变蛋白的融合蛋白

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3377484D1 (en) 1982-04-19 1988-09-01 Nissan Motor Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5976531A (en) 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
DK0531472T3 (da) 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
HU221001B1 (hu) 1994-03-17 2002-07-29 Merck Patent Gmbh. Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
EP0706799B1 (en) 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunoconjugates II
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US5980895A (en) * 1995-10-13 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
EE04025B1 (et) * 1996-02-20 2003-04-15 Applied Research Systems Ars Holding N.V. Heterodimeere moodustavad hübriidvalgud
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
DE69918146T2 (de) * 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
ES2265693T3 (es) * 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Proteinas de fusion con interferon-beta y usos.
JP4944324B2 (ja) * 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
CA2405550A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US7736652B2 (en) * 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20070003514A1 (en) 2002-04-05 2007-01-04 The Regents Of The University Of California Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
JP2004093527A (ja) * 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
US20090221477A1 (en) * 2004-07-26 2009-09-03 Asterion Limited Linkers
RU2007130552A (ru) * 2005-01-10 2009-02-20 Рисерч Дивелопмент Фаундейшн (US) Рекомбинантные молекулы направленного действия для лечения рака
CN101484182B (zh) * 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
CN101184771A (zh) * 2005-05-26 2008-05-21 先灵公司 干扰素－IgG融合体
AU2006263331B2 (en) * 2005-06-29 2012-02-16 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Recombinant interferon alpha2 (IFNalpha2) mutants
NZ542111A (en) 2005-08-30 2008-04-30 Otago Innovation Ltd Novel assay
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR101661770B1 (ko) 2007-09-21 2016-10-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함
US20100047164A1 (en) 2008-04-11 2010-02-25 Duke University Anti-Tumor Antibodies
WO2009134870A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Potent cell-binding agent drug conjugates
JP2012503203A (ja) 2008-09-19 2012-02-02 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 基底乳癌腫の診断および処置のためのｃｓｐｇ４に対するモノクローナル抗体
AU2010244428B2 (en) 2009-05-06 2015-01-29 Biotest Ag Uses of immunoconjugates targeting CD138
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy
EP2646054A4 (en) 2010-12-02 2015-03-04 Univ Pittsburgh METHOD FOR THE TREATMENT OF A TUMOR WITH THE HELP OF AN ANTIBODY FOR SPECIFIC BINDING TO GRP94
AU2012215572A1 (en) 2011-02-10 2013-05-02 Roche Glycart Ag Improved immunotherapy
WO2013050725A1 (en) 2011-10-04 2013-04-11 King's College London Ige anti -hmw-maa antibody
PL2822575T3 (pl) * 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097844A1 (en) * 2000-06-22 2001-12-27 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
CN1751122A (zh) * 2003-02-18 2006-03-22 默克专利有限公司 具有改进特性的干扰素α突变蛋白的融合蛋白

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
抗HBsAg Fab片段和α-干扰素融合蛋白的克隆及表达;郑伟等;《中华肝脏病杂志》;19981231;第6卷(第4期);摘要,第231页右栏第1段 *

Also Published As

Publication number Publication date
HK1199043A1 (en) 2015-06-19
EP2853267A1 (en) 2015-04-01
CA2699944A1 (en) 2009-03-26
BRPI0817108A2 (pt) 2015-03-31
IL233305B (en) 2018-07-31
CN101868246A (zh) 2010-10-20
MX2010003099A (es) 2010-05-17
CN108129573B (zh) 2021-10-08
AU2008302111B2 (en) 2014-04-24
KR101661770B1 (ko) 2016-10-04
US8258263B2 (en) 2012-09-04
IL233305A0 (en) 2014-08-31
EP2200634B1 (en) 2015-02-11
EP2853267B1 (en) 2016-12-07
JP2014208701A (ja) 2014-11-06
IL204644A0 (en) 2010-11-30
CN103880965A (zh) 2014-06-25
JP2017031215A (ja) 2017-02-09
US20100297076A1 (en) 2010-11-25
US20100172868A1 (en) 2010-07-08
US9139634B2 (en) 2015-09-22
IL204644A (en) 2014-07-31
CN108129573A (zh) 2018-06-08
BRPI0817108B8 (pt) 2021-05-25
JP6087871B2 (ja) 2017-03-01
EP3150218B1 (en) 2021-09-08
JP2010540453A (ja) 2010-12-24
MX349306B (es) 2017-07-19
US9534033B2 (en) 2017-01-03
US20140079668A1 (en) 2014-03-20
US20170151342A1 (en) 2017-06-01
EP2200634A4 (en) 2012-05-30
KR20160063429A (ko) 2016-06-03
AU2008302111A1 (en) 2009-03-26
BRPI0817108B1 (pt) 2020-04-22
JP5591701B2 (ja) 2014-09-17
WO2009039409A1 (en) 2009-03-26
KR20100084634A (ko) 2010-07-27
US8563692B2 (en) 2013-10-22
CA2699944C (en) 2017-11-14
KR101759460B1 (ko) 2017-07-18
US10182984B2 (en) 2019-01-22
EP3150218A1 (en) 2017-04-05
ES2536772T3 (es) 2015-05-28
US20110104112A1 (en) 2011-05-05
EP2200634A1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
CN103880965B (zh) 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
US10822427B2 (en) Anti-CSPG4 fusions with interferon for the treatment of malignancy
US10975158B2 (en) CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
JP2018502147A (ja) タンパク性ヘテロ二量体及びその使用
KR20230061392A (ko) 수용체 쌍형성과 관련된 조성물 및 방법
JP2024542021A (ja) ペイロードのｉｎ ｖｉｖｏ標的化送達用のテトラジンコンジュゲート
HK1199043B (en) Targeted interferon demonstrates potent apoptotic and anti-tumor activities

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1199043

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant